Intervention Protocol

Steroid sparing drug treatments for giant cell arteritis

  1. Catherine L Hill1,*,
  2. Antonia Cole2,
  3. Sue Lester3,
  4. Samuel L Whittle1

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 21 JAN 2009

DOI: 10.1002/14651858.CD005323.pub2


How to Cite

Hill CL, Cole A, Lester S, Whittle SL. Steroid sparing drug treatments for giant cell arteritis (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD005323. DOI: 10.1002/14651858.CD005323.pub2.

Author Information

  1. 1

    The Queen Elizabeth Hospital, Rheumatology Unit, Woodville, South Australia, Australia

  2. 2

    The Queen Elizabeth Hospital, Woodville, South Australia, Australia

  3. 3

    Hanson Institute, Arthritis Research Lab, Adelaide, South Australia, Australia

*Catherine L Hill, Rheumatology Unit, The Queen Elizabeth Hospital, 28 Woodville Rd, Woodville, South Australia, 5011, Australia. Catherine.Hill@nwahs.sa.gov.au.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The aim of this systematic review is to document the quality and quantity of available evidence guiding practitioners in the use of glucocorticoid-sparing medications in the treatment of GCA. Specific objectives are:

  • To assess the effectiveness of corticosteroid-sparing drug regimens